S-23 10mg/tab 30 Tablets by Vital Research

Usage

1. Review your baseline bloodwork — testosterone, LH, FSH, and liver enzymes — before beginning any S-23 protocol, to establish a pre-cycle reference point for comparing suppression against your personal baseline rather than population averages.
2. Start at 10 mg/day (one tablet) with a meal to minimize gastrointestinal sensitivity; the tablet is not designed for sublingual use.
3. Maintain a consistent dosing time each day — S-23's half-life of approximately 12 hours supports once-daily dosing, but consistency minimises peak-trough variation that could blur assessment of tissue-selective effects.
4. At the transition to 20 mg/day, introduce the second tablet with the same meal rather than splitting doses across morning and evening, unless blood-level stability is a specific research objective.
5. Track androgenic indicators (libido, mood, energy) weekly as practical proxies for HPG-axis status — the same markers relevant when monitoring AAS cycles, and directly informative for the selectivity comparison the S-23 angle centres on.
6. Plan and procure PCT agents before cycle start; do not treat post-cycle recovery as optional — S-23 suppression data from preclinical models indicates recovery requires active intervention, not passive time alone.

Warnings

Frequently asked questions

What does 'selective' actually mean when comparing S-23 to anabolic steroids?

Selectivity refers to the preferential binding and activation of androgen receptors in specific tissues — primarily skeletal muscle and bone — over other AR-expressing tissues such as the prostate, skin, or liver. Classic anabolic steroids activate androgen receptors broadly across all tissues. S-23's nonsteroidal molecular structure allows a different receptor-coactivator interaction pattern, producing a tissue-weighted response that preclinical organ-weight models confirm favours levator ani over prostate.

Does S-23 cause liver damage the way oral anabolic steroids do?

S-23 is not 17-alpha-alkylated, the chemical modification responsible for hepatotoxicity in oral AAS such as Dianabol or Winstrol. That specific hepatic-stress pathway is therefore absent with S-23. However, any orally administered compound undergoes first-pass hepatic processing, and long-term or high-dose use has not been studied in human clinical trials, so baseline liver enzyme monitoring remains a sensible precaution.

Will S-23 suppress testosterone, and is that different from what steroids do?

Yes — S-23 suppresses the HPG axis dose-dependently, lowering LH, FSH, and endogenous testosterone. This is pharmacologically similar to AAS suppression, making it one area where the SARM/steroid distinction narrows significantly. The degree of suppression is generally considered greater than milder SARMs like Ostarine and may approach AAS-level suppression at higher doses, which is why structured PCT is mandatory after an S-23 cycle.

Can the 10 mg tablet be split for lower doses?

Each tablet is manufactured to deliver 10 mg of S-23 as a single unit. Splitting is physically possible with a pill cutter but is not recommended, as content uniformity within a single tablet cannot be guaranteed after splitting. The 10 mg per-tablet format is intentional — it represents the smallest discrete dose increment available in this blister, allowing precise step-up protocols without liquid measurement.

How long does one 30-tablet blister of Vital Research S-23 last?

At 10 mg per day — a common starting point in research protocols — one 30-tablet blister covers exactly 30 days. At 20 mg per day the same blister provides a 15-day supply. Each blister is sealed and individually coded, so it remains shelf-stable and tamper-evident throughout that period. Vital Research's HPLC certificate of analysis for each lot confirms potency is maintained at the declared 10 mg per tablet. (2) angle_used

Manufacturer

Vital Research's API sourcing strategy for its SARM portfolio is governed by compound-specific purity specifications rather than a blanket supplier approval covering all active ingredients collectively. For S-23 in particular, raw-material acceptance criteria are defined against the nonsteroidal chloro-substituted molecular structure of the compound — identity confirmation, chromatographic purity thresholds, and residual-solvent limits are each set at the API level before any tablet manufacturing begins. This upstream specificity is what underpins the downstream HPLC potency claim on each blister's certificate of analysis: the declared 10 mg per tablet is traceable to an API lot that cleared compound-specific incoming-goods testing, not to a facility-wide approval that would apply equally to chemically unrelated compounds in the same production environment.